The global live biotherapeutic products and microbiome CDMO market size is calculated at USD 76.77 million in 2025 and is forecasted to reach around USD 1,496.69 million by 2034, accelerating at a CAGR of 39.10% from 2025 to 2034. The North America market size surpassed USD 39.74 million in 2024 and is expanding at a CAGR of 39.19% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Live Biotherapeutic Products and Microbiome CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Live Biotherapeutic Products and Microbiome CDMO Market, by Application Type
8.1.1. C. Difficile
8.1.1.1. Market Revenue and Forecast
8.1.2. Crohn’s Disease
8.1.2.1. Market Revenue and Forecast
8.1.3. IBS
8.1.3.1. Market Revenue and Forecast
8.1.4. Diabetes
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Application
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Application
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Application
9.2. Europe
9.2.1. Market Revenue and Forecast, by Application
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Application
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Application
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Application
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Application
9.3. APAC
9.3.1. Market Revenue and Forecast, by Application
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Application
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Application
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Application
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Application
9.4. MEA
9.4.1. Market Revenue and Forecast, by Application
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Application
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Application
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Application
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Application
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Application
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Application
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Application
10.1. Arrant Bio
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. 4D Pharma
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Cerbios
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Biose Industrie
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Assembly Biosciences, Inc.
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Wacker Chemie AG
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Quay Pharmaceuticals
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. NIZO
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Lonza
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Inpac Probiotics
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
12.1. About Us
12.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample